Maze Therapeutics, Inc.
NASDAQ:MAZEBiotechnology
+$0.18 today
- Market cap
- $1.71B
- Beta
- 2.26
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.27
Volume 0.71M
Average 0.84M
MAZE Purchases of Investments
Cash used to buy marketable securities and other investments.
Maze Therapeutics, Inc.NASDAQ: MAZE
Purchases of Investments · Q1 FY2026 · quarter ended Mar 2026
Purchases of investments turns negative
Q1 FY2026 purchases of investments was -$23.63M, compared with $0 a year earlier. Trailing-twelve-month purchases of investments was -$211.3M.
Context
- Purchases of investments increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly purchases of investments holds near -$23.63M or moves back toward the trailing-twelve-month quarterly average of -$52.83M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Purchases of Investments history
USD · from the cash flow
- Latest · FY2025
- (187.67M) USD
- Year-over-year change
- —
| Period | Period end | Purchases of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (187.67M) | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
Purchases of Investments vs competitors
How MAZE compares with its peers on the latest reported figures
- Peers report in different currencies, so purchases of investments is compared through growth and share of revenue rather than absolute size.
- Purchases of investments amounts to 1056.5% of revenue for MAZE, versus a peer median of 295.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.51B USD | +23.3% | +165.7% | 149.5% | |
| LTM Sep 2026 | $451.24M USD | +131.4% | -14.9% | 69.3% | |
SEPNSepterna, Inc. | LTM Sep 2026 | $424.9M USD | +14.5% | — | 441.4% |
| LTM Mar 2026 | $235.25M USD | +22.1% | +63.2% | 55.0% | |
| LTM Mar 2026 | $211.3M USD | — | — | 1056.5% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $157.4M USD | +102.9% | — | 1525.8% |
| FY2025 | €127.69M EUR | — | +4935.6% | 2848.4% | |
| LTM Mar 2026 | $71.79M USD | +51.2% | +9.1% | — | |
| Peer median (excluding MAZE) | — | +37.2% | +63.2% | 295.4% | |
Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Maze Therapeutics, Inc.
NASDAQ:MAZE
Intrinsic Alpha fair value
Locked
Current Price
$31.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.